Pantogam was used as a corrector of the side-effects of neuroleptic therapy. The adverse effects were assessed psychometrically with several scales. Attention was focused on the unwanted signs (pathological movements of different groups of muscles). Fifty patients were studied, 37 of them completed the treatment course. Pantogam was administered in dosage 750-3000 mg per day along with traditional and atypical neuroleptics. The drug was effective against the most prevalent side-effects. The mild sedative effect of pantogam, absence of negative influence on myocardial vessels and possibility of its combination with most pharmacological drugs make its possible to use the drug in patients of different age groups.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Clinical and psychological manifestations of emotional burnout in mothers of children with neuropsychiatric diseases (on a model of ADHD)].
Zh Nevrol Psikhiatr Im S S Korsakova
February 2023
N. Bekhtereva Institute of Human Brain Russian Academy of Sciences, St. Petersburg, Russia.
Objective: To evaluate the therapeutic efficacy of Pantogam aktiv in the treatment of clinical manifestations of burnout in mothers of children with ADHD.
Material And Methods: Under observation were 108 mothers of children with attention deficit hyperactivity disorder (ADHD) aged 25 to 50 years, who had symptoms of burnout in the clinical picture during the initial visit. The following research methods were used in the work: clinical history taking, neurological examination, S.
[Pharmacotherapy of psychomotor developmental delay in 6-12 months preterm infants with hypoxic-ischemic encephalopathy (the double-blind comparative multicenter placebo-controlled study)].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2019
Samara State Medical University, Samara, Russia.
Aim: To evaluate the efficacy and safety of hopantenic acid (Pantogam) in the complex treatment of prematurely born infants, aged 6-12 months, with psychomotor developmental delay due to hypoxic-ischemic encephalopathy.
Material And Methods: Eighty-seven patients were randomized into two groups: 44 received standardized treatment and pantogam for two months, 43 standardized treatment and placebo. Pantogam (syrup 100 mg/ml) or placebo were prescribed orally 15-30 minutes after feeding, twice a day, in a daily dosage of 30-50 mg/kg body weight.
[Pharmacotherapy of attention deficit hyperactivity disorder in children: the results of a multicenter double-blind placebo-controlled study of hopantenic acid].
Zh Nevrol Psikhiatr Im S S Korsakova
November 2018
National Scientific and Practical Center of Children's Health, Moscow, Russia.
Aim: To assess the efficacy and safety of hopantenic acid (pantogam) compared to placebo in the treatment of attention deficit hyperactivity disorder (ADHD) in children, aged from 6 to 12 years, during 4 month in the prospective multicenter comparative double-blind placebo-controlled study in parallel groups.
Material And Methods: One hundred patients enrolled in the safety assessment population were stratified into two equal pantogam and placebo groups. Eighty-nine patients who completed the study in according to the protocol were included in the efficacy assessment group: 45 in the pantogam group and 44 in the placebo group.
[Possible applications of rac-hopantenic acid in the treatment of anxiety and depressive disorders in patients with chronic cerebral ischemia].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2018
Scientific and Practical Neuropsychiatric Center, Moscow Health Department, Moscow, Russia.
Aim: To evaluate the efficacy and tolerability of rac-hopantenic acid (pantogam activ) in patients with mixed anxiety-depressive disorder and anxiety-depressive disorder with chronic cerebral ischemia.
Material And Methods: A total of 50 patients were examined (30 patients in the main group, 20 patients in the control one). All patients received standard therapy with SSRI antidepressants.
[Augmented antipsychotic therapy with pantogam active in patients with schizophrenia].
Zh Nevrol Psikhiatr Im S S Korsakova
November 2015
Medical University, People's Friendship University of Russia, Moscow; Psychiatric Hospital #13, Moscow.
Objective: to study the efficacy of the GABA-ergic drug pantogam active (D-, L-gopantenic acid) in patients with schizophrenia treated with typical neuroleptics and to assess the rate of treatment response and tolerability of the drug.
Material And Methods: A sample consisted of 70 patients with schizophrenia stratified into main (n=35) and control (n=35) groups. All patients received one of typical antipsychotics (haloperidol, zuclopenthixol, promazine or perphenazine).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!